Biological therapies: New treatment options for ANCA-associated vasculitis?

Expert Opinion on Biological Therapy

Volumn 7, Issue 4, 2007, Pages 521-533

  Aries, Peer M ^a   Lamprecht, Peter ^b   Gross, Wolfgang L ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b NONE

Author keywords

Biologics; Etanercept; Infliximab; Interferon; Rituximab; Vasculitis

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL RESPONSE MODIFIER; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANCA ASSOCIATED VASCULITIS; ARTHRALGIA; B LYMPHOCYTE; BIOLOGICAL THERAPY; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; FEVER; FLU LIKE SYNDROME; HEADACHE; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; HYPOGAMMAGLOBULINEMIA; HYPOTENSION; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; INFECTION; INJECTION SITE REACTION; LEUKOCYTOCLASTIC VASCULITIS; LEUKOENCEPHALOPATHY; LIVER TOXICITY; MALAISE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROLOGIC DISEASE; PLASMA CELL; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SOLID TUMOR; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEGENER GRANULOMATOSIS; BLOOD; DRUG ANTAGONISM; EXPERT WITNESS; IMMUNOLOGY; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; BIOLOGICAL THERAPY; CHURG-STRAUSS SYNDROME; EXPERT TESTIMONY; HUMANS; IMMUNOGLOBULIN G; INTERFERON-ALPHA; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 34047137004     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.4.521     Document Type: Review

References (67)

1. HOFFMAN GS, KERR GS, LEAVITT RY et al.: Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med. (1992) 116(6):488- 498. • This has been the first comprehensive cohort analysis for WG.
2. REINHOLD-KELLER E, BEUGE N, LATZA U et al.: An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. (2000) 43(5):1021-1032.
3. HELLMICH B, LAMPRECHT P, GROSS WL: Advances in the therapy of Wegener's granulomatosis. Curr. Opin. Rheumatol. (2006) 18(1):25-32.
4. REINHOLD-KELLER E, FINK CO, HERLYN K, GROSS WL, DE GROOT K: High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum. (2002) 47(3):326-332.
5. SPECKS U: Antineutrophil cytoplasmatic antibodies: are they pathogenic? Clin. Exp. Rheumatol. (2004) 22(36):S7-S12. • This is a clear review on the recent finding on the role of ANCA in ANCA-associated vasculitides.
6. PENDERGRAFT WV, PRESSLER BM, JENNETTE JC, FALK RJ, PRESTON GA: Autoantigen complementarity: a new theory implicating cpmplemetary propteins as initiators of autoimmune disease. J. Mol. Med. (2005) 83(1):12-25.
7. CSERNOK E, AI M, GROSS WL et al.: Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. Blood (2006) 107(11):4440- 4448. • • This is a pioneering work focusing on the initial mechanisms in the pathogenesis of ANCA-associated vasculitis.
8. VOSWINKEL J, MUELLER A, KRAEMER JA et al.: B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann. Rheum. Dis. (2006) 65(7):859-864.
9. JAYNE DR, LOCKWOOD CM: High-dose pooled immunoglobulin in the therapy of systemic vasculitis. Trans. Assoc. Am. Phys. (1991) 104:304-312.
10. JAYNE DR, DAVIES MJ, FOX CJ, BLACK CM, LOCKWOOD CM: Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet (1991) 337(8750):1137-1139.
11. MATHIESON PW, COBBOLD SP, HALE G et al.: Monoclonal-antibody therapy in systemic vasculitis. N. Engl J. Med. (1990) 323(4):250-254.
12. RICHTER C, SCHNABEL A, CSERNOK E, REINHOLD-KELLER E, GROSS WL: Treatment of Wegener's granulomatosis with intravenous immunoglobulin. Adv. Exp. Med. Biol. (1993) 336:487-489.
13. JAYNE D: What place for the new biologics in the treatment of necrotising vasculitides. Clin. Exp. Rheumatol. (2006) 24(2Suppl. 41):S1-S5.
14. GROSS WL: Immunopathology and new therapeutic considerations in ANCA-associated vasculitides. Autoimmun. Rev. (2004) 3(Suppl.1): S47-S8.
15. NORONHA IL, KRUGER C, ANDRASSY K, RITZ E, WALDHERR R: In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int. (1993) 43:682-692.
16. PFISTER H, OLLERT M, FROHLICH LF et al.: Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood (2004) 104:1411-1418. •• This has been the first in vivo model for the pathogenic role of PR3-ANCA.
17. HUUGEN D, XIAO H, VAN ESCH A et al.: Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am. J. Pathol. (2005) 167:47-58.
18. LAMPRECHT P, CSERNOK E, GROSS WL: Effector memory T cells as driving force of granuloma formation and autoimmunity in Wegener's granulomatosis. J.Intern.Med. (2006) 260:187-191.
19. HELLMICH B, CSERNOK E, GROSS WL: Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann. NY Acad.Sci. (2005) 1051:121-131. • This is a comprehensive review on the cytokine network in CSS.
20. SARRAF P, SNELLER M: Pathogenesis of Wegener's granulomatosis: Current concepts. Expert Rev. Mol. Med. (2005) 7:1-19. •• A unique review on the pathogenesis of WG considering all aspects of the development of granulomatous disease and vasculitis.
21. - T-cells are a major source of IFN-γ and TNF-α in Wegerner's granulomatosis. Am. J. Pathol. (2002) 160:1717-1724.
22. ZINKERNAGEL RM: On reactivity versus tolerance. Immunol. Cell Biol. (2004) 82:343-352.
23. LITTLE MA, BHANGAL G, SMYTH L et al.: Therpeutic effect of anti-TNF-α antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. (2006) 17:160-169.
24. SCALLON B, CAI A; SOLOWSKI N et al.: Binding and functional comparison of two types of tumor necrosis factor antagonists. J. Pharm. Exp. Ther. (2002) 301:418-426.
25. REIMOLD AM: New indications for treatment of chronic inflammation by TNF-alpha blockade. Am. J. Med. Sci. (2003) 325:75-92.
26. LAMPRECHT P, VOSWINKEL J, LILIENTHAL T et al.: Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) (2002) 41(11):1303-1307.
27. KLEINERT J, LORENZ M, KOSTLER W, HORL W, SUNDER-PLASSMANN G, SOLEIMAN A: Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. Wien. Klin. Wochenschr. (2004) 116(9-10):334-338.
28. MUKHTYAR C, LUQMANI R: Current state of tumour necrosis factor α blockade in Wegener's granulomatosis. Ann. Rheum. Dis. (2005) 64(Suppl. 4):31-36.
29. STONE JH, UHLFELDER ML, HELLMANN DB, CROOK S, BEDOCS NM, HOFFMAN GS: Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. (2001) 44(5):1149-1154.
30. WEGENER'S GRANULOMATOSIS ETANERCEPT TRIAL (WGET) RESEARCH GROUP: Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl J. Med. (2005) 352(4):351-361. • The only randomized controlled study investigating biological therapies in ANCA-associated vasculitides.
31. STONE JH: Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Wegener's Granulomatosis Etanercept Trial Research Group. Arthritis Rheum. (2003) 48(8):2299-309.
32. WGET RESEARCH GROUP: Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin. Trials (2002) 23(4):450-468.
33. LAMPRECHT P, KUMANOVICS G, MUELLER A et al.: Elevated monocytic IL-12 and TNF-alpha production in Wegener's granulomatosis is normalized by cyclophosphamide and corticosteroid therapy. Clin. Exp. Immunol. (2002) 128(1):181-186.
34. TATSIS E, REINHOLD-KELLER E, STEINDORF K, FELLER AC, GROSS WL: Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum. (1999) 42(4):751-756. • A pioneering article about the overall risk of cancer in WG.
35. HARAQUI B: Differentiating the efficacy of tumor necrosis factor inhibitors. J. Rheumatol. (2005) 32(74):3-7.
36. TARGAN SR, HANAUER SB, VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. (1997) 337(15):1029-1035.
37. SANDBORN WJ, HANAUER SB, KATZ S et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 121(5):1088-1094.
38. MOHAN N, EDWARDS ET, CUPPS TR et al.: Leucocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J. Rheumatol. (2004) 31:1955-1958.
39. NESTOROV I: Clinical pharmacokinetics of tumor necrosis factor antagonists. J. Rheumatol. Suppl. (2005) 74:13-18.
40. GOMEZ-REINO JJ, CARMONA L, VALVERDE VR, MOLA EM, MONTERO MD: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. BIOBADASER Group. Arthritis Rheum. (2003) 48(8):2122-2127.
41. SILVERMAN GJ, WEISMAN S: Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. (2003) 48(6):1484-1492.
42. REFF ME, CARNER K, CHAMBERS KS et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 83(2):435-445.
43. SCHRODER C, AZIMZADEH AM, WU G, PRICE JO, ATKINSON JB, PIERSON RN: Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl. Immunol. (2003) 12(1):19-28.
44. MALONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al.: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 90(6):2188-2195.
45. PROTHEROE A, EDWARDS JC, SIMMONS A, MACLENNAN K, SELBY P: Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology (Oxford) (1999) 38(11):1150-1152.
46. EMERY P, FLEISCHMANN R, FILIPOWICZ-SOSNOWSKA A et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a Phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. DANCER Study Group. Arthritis Rheum. (2006) 54(5):1390-1400.
47. VIGNA-PEREZ M, HERNANDEZ-CASTRO B, PAREDES-SAHAROPULOS O et al.: Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. (2006) 8(3):R83.
48. PIJPE J, VAN IMHOFF GW, SPIJKERVET FK et al.: Rituximab treatment in patients with primary Sjogren's syndrome: an open-label Phase II study. Arthritis Rheum. (2005) 52(9):2740-2750.
49. TEKTONIDOU MG, SKOPOULI FN: Sustained 3-year remission after rituximab treatment in a patient with refractory Wegener's granulomatosis. Clin. Exp. Rheumatol. (2006) 24(2Suppl. 41):S103.
50. LOONEY RJ, ANOLIK JH, CAMPBELL D et al.: B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. (2004) 50(8):2580-2589.
51. HOYER BF, MANZ RA, RADBRUCH A, HIEPE F: Long-lived plasma cells and their contribution to autoimmunity. Ann. NY Acad. Sci. (2005) 1050:124-133. • An important contribution to the possible role of long-living plasma cells in autoimmune diseases, especially in the context of the first studies on rituximab in ANCA-associated vasculitis.
52. ARIES PM, HELLMICH B, VOSWINKEL J et al.: Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann. Rheum. Dis. (2006) 65(7):853-858.
53. ERIKSSON P: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J. Intern. Med. (2005) 257(6):540-548.
54. OMDAL R, WILDHAGEN K, HANSEN T, GUNNARSSON R, KRISTOFFERSEN G: Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand. J. Rheumatol. (2005) 34(3):229-232.
55. FALK RJ, JENNETTE JC: ANCA are pathogenic-oh yes they are! J. Am. Soc. Nephrol. (2002) 13(7):1977-1979.
56. SANDERS JS, STEGEMAN CA, KALLENBERG CG: The Th1 and Th2 paradigm in ANCA-associated vasculitis. Kidney Blood Press. Res. (2003) 26(4):215-220.
57. SNELLER MC: Granuloma formation, implications for the pathogenesis of vasculitis. Cleve. Clin. J. Med. (2002) 69(Suppl. 2):SII40-SII43.
58. LEANDRO MJ, COOPER N, CAMBRIDGE G, EHRSTEIN MR, EDWARDS JC: Bone marrow B-lineage cells in patients with rheumaroid arthritis following rituximab therapy, Rheumatology (2007) 46(1):29-36. •• The first clinical data on the effect of rituximab beyond peripheral B cell depletion in rheumatoid arthritis.
59. GROSS WL: Churg-Strauss syndrome: update on recent developments. Curr. Opin. Rheumatol. (2002) 14(1):11-14.
60. KRISHNASWAMY G, SMITH JK, SRIKANTH S, CHI DS, KALBFLEISCH JH, HUANG SK: Lymphoblastoid interferon-alpha inhibits T cell proliferation and expression of eosinophil-activating cytokines. J. Interferon Cytokine Res. (1996) 16(10):819-827.
61. ALDEBERT D, LAMKHIOUED B, DESAINT C et al.: Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators. Blood (1996) 87(6):2354-2360.
62. METZLER C, LAMPRECHT P, HELLMICH B, REUTER M, ARLT AC, GROSS WL: Leucoencephalopathy after treatment of Churg-Strauss syndrome with interferon alpha. Ann. Rheum. Dis. (2005) 64(8):1242-1243.
63. KAMAR N, KANY M, BORIES P et al.: Reversible posterior leukoencephalopathy syndrome in hepatitis C virus-positive long-term hemodialysis patients. Am. J. Kidney Dis. (2001) 37(4):E29.
64. RE D, BAMBORSCHKE S, FEIDEN W et al.: Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Bone Marrow Transplant. (1999) 23(3):295-298.
65. AKWA Y, HASSETT DE, ELORANTA ML et al.: Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J. Immunol. (1998) 161(9):5016-5026.
66. WANG J, SCHREIBER RD, CAMPBELL IL: STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-alpha in the central nervous system. Proc. Natl. Acad Sci. USA (2002) 99(25):16209- 16214.
67. HEWINS P, MORGAN MD, HOLDEN N et al.: IL 18 is upreguletad in the kidney and primes neutrophil responsivess in ANCA-associated vasculitis, Kidney Int. (2006) 69:605-615.